Man Group plc Invests $342,000 in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Man Group plc purchased a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 62,900 shares of the biopharmaceutical company's stock, valued at approximately $342,000. Man Group plc owned 0.10% of Sage Therapeutics as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Nomura Holdings Inc. bought a new stake in Sage Therapeutics during the fourth quarter valued at approximately $165,000. Millennium Management LLC grew its position in Sage Therapeutics by 8.3% during the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company's stock valued at $8,817,000 after buying an additional 124,720 shares during the period. Lazard Asset Management LLC bought a new stake in Sage Therapeutics during the fourth quarter valued at approximately $1,209,000. Deutsche Bank AG grew its position in Sage Therapeutics by 67.6% during the fourth quarter. Deutsche Bank AG now owns 50,818 shares of the biopharmaceutical company's stock valued at $276,000 after buying an additional 20,504 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its position in Sage Therapeutics by 18.8% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 720,105 shares of the biopharmaceutical company's stock valued at $3,910,000 after buying an additional 114,173 shares during the period. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Stock Performance

SAGE stock traded down $0.04 during mid-day trading on Wednesday, reaching $6.48. 673,816 shares of the stock traded hands, compared to its average volume of 1,194,157. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $13.47. The stock has a market capitalization of $405.78 million, a PE ratio of -0.98 and a beta of 0.20. The business has a 50-day moving average price of $7.23 and a two-hundred day moving average price of $6.74.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The firm had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter last year, the firm earned ($1.80) EPS. The company's revenue was up 78.0% on a year-over-year basis. On average, equities analysts expect that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Wedbush restated a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a report on Friday, April 25th. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Bank of America began coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target on the stock. Finally, Scotiabank lowered their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.